MedPath

Temozolomide in children with recurrent or refractory CNS tumors.

Recruiting
Conditions
recurrent primitive neuro ectodermal tumors and recurrent high grade gliomas of the CNS in children.
Registration Number
NL-OMON28755
Lead Sponsor
SKION (Stichting Kinder Oncologie); Schering Plough
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
54
Inclusion Criteria

1. Age 3-18;

2. Pathology: PNET/high grade glioma
measurable tumor;

Exclusion Criteria

Non conformation to inclusion criteria.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Difference in MRI respons after 12 weeks between the 2 arms.
Secondary Outcome Measures
NameTimeMethod
Difference in side effects after 12 weeks between the 2 arms.
© Copyright 2025. All Rights Reserved by MedPath